273 related articles for article (PubMed ID: 10698518)
21. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
22. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
[TBL] [Abstract][Full Text] [Related]
23. Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer.
Kronblad A; Helczynska K; Nielsen NH; Påhlman E; Emdin S; Påhlman S; Landberg G
In Vivo; 2003; 17(4):311-8. PubMed ID: 12929585
[TBL] [Abstract][Full Text] [Related]
24. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
25. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
26. A new cis element is involved in the HER2 gene overexpression in human breast cancer cells.
Grooteclaes M; Vernimmen D; Plaza S; Pasleau F; Hodzic D; Winkler-Gol R
Cancer Res; 1999 Jun; 59(11):2527-31. PubMed ID: 10363966
[TBL] [Abstract][Full Text] [Related]
27. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations.
Cuny M; Simony-Lafontaine J; Rouanet P; Grenier J; Valles H; Lavaill R; Louason G; Causse A; Lequeux N; Thierry C
Oncol Res; 1994; 6(4-5):169-76. PubMed ID: 7841539
[TBL] [Abstract][Full Text] [Related]
28. High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers.
Brimmell M; Burns JS; Munson P; McDonald L; O'Hare MJ; Lakhani SR; Packham G
Br J Cancer; 1999 Nov; 81(6):1042-51. PubMed ID: 10576663
[TBL] [Abstract][Full Text] [Related]
29. A conditional version of the Ets transcription factor Erm by fusion to the ligand binding domain of the oestrogen receptor.
Pelczar H; Albagli O; Chotteau-Lelievre A; Damour I; de Launoit Y
Biochem Biophys Res Commun; 1997 Oct; 239(1):252-6. PubMed ID: 9345304
[TBL] [Abstract][Full Text] [Related]
30. Regulation of estrogen receptor activation of the prolactin enhancer/promoter by antagonistic activation function-2-interacting proteins.
Schaufele F
Mol Endocrinol; 1999 Jun; 13(6):935-45. PubMed ID: 10379892
[TBL] [Abstract][Full Text] [Related]
31. Cooperation between the human estrogen receptor (ER) and MCF-7 cell-specific transcription factors elicits high activity of an estrogen-inducible enhancer from the trout ER gene promoter.
Lazennec G; Kern L; Salbert G; Saligaut D; Valotaire Y
Mol Endocrinol; 1996 Sep; 10(9):1116-26. PubMed ID: 8885246
[TBL] [Abstract][Full Text] [Related]
32. Estrogen induces repression of the breast cancer and salivary gland expression gene in an estrogen receptor alpha-dependent manner.
Bretschneider N; Brand H; Miller N; Lowery AJ; Kerin MJ; Gannon F; Denger S
Cancer Res; 2008 Jan; 68(1):106-14. PubMed ID: 18172302
[TBL] [Abstract][Full Text] [Related]
33. Strong association between c-myb and oestrogen-receptor expression in human breast cancer.
Guérin M; Sheng ZM; Andrieu N; Riou G
Oncogene; 1990 Jan; 5(1):131-5. PubMed ID: 2181374
[TBL] [Abstract][Full Text] [Related]
34. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
[TBL] [Abstract][Full Text] [Related]
35. Interrogating the genome to understand oestrogen-receptor-mediated transcription.
Dietz SC; Carroll JS
Expert Rev Mol Med; 2008 Apr; 10():e10. PubMed ID: 18377699
[TBL] [Abstract][Full Text] [Related]
36. Copine-III interacts with ErbB2 and promotes tumor cell migration.
Heinrich C; Keller C; Boulay A; Vecchi M; Bianchi M; Sack R; Lienhard S; Duss S; Hofsteenge J; Hynes NE
Oncogene; 2010 Mar; 29(11):1598-610. PubMed ID: 20010870
[TBL] [Abstract][Full Text] [Related]
37. Ets regulation of the erbB2 promoter.
Scott GK; Chang CH; Erny KM; Xu F; Fredericks WJ; Rauscher FJ; Thor AD; Benz CC
Oncogene; 2000 Dec; 19(55):6490-502. PubMed ID: 11175365
[TBL] [Abstract][Full Text] [Related]
38. Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells.
Wilson MA; Chrysogelos SA
J Cell Biochem; 2002; 85(3):601-14. PubMed ID: 11968000
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer.
Gee JM; Robertson JF; Ellis IO; Nicholson RI; Hurst HC
J Pathol; 1999 Dec; 189(4):514-20. PubMed ID: 10629551
[TBL] [Abstract][Full Text] [Related]
40. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells.
Delacroix L; Begon D; Chatel G; Jackers P; Winkler R
DNA Cell Biol; 2005 Sep; 24(9):582-94. PubMed ID: 16153159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
